Cardio-Oncology: An Emerging Paradigm in Modern Medicine (Volume II)

Dear Colleagues,

Tremendous strides have been made in improving oncological outcomes with innovation and dedicated research. However, the success has been marred by an increase in cardiovascular events in cancer patients. This is also overshadowed by the fact that cardiovascular disease (CVD) remains the number one cause of morbidity and mortality. While disease processes (cancer and heart disease) are independent causes of increased mortality, recent evidence suggests that they are intertwined. Therefore, the mitigation of risk factors from one (such as CVD) can protect patients from the other (such as cancer). In this Special Issue, our aim is to highlight the significant points of intersection between CVD and cancer. This will be achieved by discussing the major clinical implications regarding the prevention, diagnosis, management, and treatment of cardio-oncological diseases/syndromes. A salient aspect of the Issue will be the current state of the field and what the future holds for cardio-oncological patients. 

Cancer and cardiovascular disease are the two most common causes of death worldwide. As the fields of cardiovascular medicine and oncology continue to expand, the area of overlap is becoming more prominent, demanding dedicated attention and individualized patient care. We have come to realize that both fields are inextricably intertwined in several aspects, so much so that the mere presence of one, with its resultant downstream implications, has an impact on the other. Nonetheless, cardiovascular disease and cancer are generally approached independently. The focus that is granted to the predominant pathological entity (either cardiovascular disease or cancer) does not allow for optimal medical care for the other. As a result, ample opportunities for improvement in overall health care are being overlooked. Herein, we hope to shed light on the interconnected relationship between cardiovascular disease and cancer, and to uncover some of the unintentionally neglected intricacies of common cardiovascular therapeutics from an oncologic standpoint. 

We are pleased to invite you: 

• To contribute to this one-of-a-kind Special Issue dedicated to discussing the past, present and, most importantly, future of this field. We would like to establish the current state of this field so that as we move forward, we have a clear picture of past research, a considerable understanding of today’s ongoing work, and a forecast of potential knowledge gaps and areas of interest to accelerate the advancement in cardio-oncology. 
• This Special Issue aims to: 
• Highlight the basic science of cardiotoxicity to cancer-related therapies.
• Highlight clinical trials, research and studies that have shed light on the importance of and advancements in cardio-oncology.
• Highlight social determinants, inequalities, and racial/ethnic disparities that still hinder the deployment of equitable care.
• Enable future directions with the development of global registries and the deployment of artificial intelligence.

We look forward to receiving your contributions.

Dr. Rohit Moudgil
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• cardio-oncology
• CTRCD
• arrhythmias
• anthracyclines
• anti-her2 therapies
• immune checkpoint inhibitors
• artificial intelligence
• guidelines
• emerging research